IN-USE TOLERANCE STUDY UNDER DERMATOLOGICAL AND OPHTHALMOLOGICAL CONTROLS AND EFFICACY ASSESSMENT
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 33
- 试验地点
- 1
- 主要终点
- Global tolerance assessment of the investigational product by dermatological evaluation
研究概览
简要总结
The aim of this study is to assess the dermatological and ophthalmological tolerance of the investigational product Baume visage / Face balm RV4942A - RY1985 after 21 days of twice daily use on the study areas, under normal conditions of use.
The aim of this study is also to:
- evaluate the cutaneous sensitivity by a stinging test at D1 T0 and D22.
- evaluate the cutaneous sensitivity by a sensitive scale at D1 T0, D1 Timm*, D8 and D22.
- evaluate the soothing efficacy by an efficacy questionnaire at D1 Timm*, D8 and D22.
- evaluate the cosmetic acceptability by a questionnaire at D22.
This study is conducted as a national, monocentric, non-randomized open trial. The 33 subjects in this study (31 subjects on D22) present hypersensitive, reactive and intolerant skin on face. They are stinger subjects, with a dry to very dry skin.
Timm*: 10 to 30 minutes after first application
详细描述
his study is a national, monocentric, non-randomized open trial, conducted in adults presenting hypersensitive, reactive and intolerant skin on the face, with a dry to very dry skin.
The study includes 3 visits, including subjects' selection:
- V1: Baseline inclusion
- V2: 1 week, intermediate visit
- V3: 3 weeks, study end
The maximal study duration is 25 days.
The evaluation is at 3 times: D1 baseline, D8 at 1 week and D22 at 3 weeks of application of RV4942A - RY1985 with comparison of each time versus baseline.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Other
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Criteria related to the population:
- •Male or Female aged between 18 and 65 years included
- •Asian population (Chinese origin)
- •Dry to very dry skin on the face
- •Subject with phototype I to IV included
- •Subject having signed his/her written informed consent for his/her participation in the study
- •Subject who is currently not participating in another clinical study
- •Subject affiliated to a social security system or health insurance, or is a beneficiary
- •For woman of childbearing potential: use of an effective method of contraception and using it during the whole duration of the study
- •Criteria related to diseases and general health:
- •Stinger subjects (evaluated by a stinger test)
- •Subject with hypersensitive, reactive and intolerant skin on face
- •Subject having a score superior to 4 on a sensitive scale for tightness parameter on the face
- •Subject having a score superior to 4 on a sensitive scale for general discomfort parameter on the face
排除标准
- •Criteria related to the population:
- •For woman of childbearing potential: subject pregnant or breastfeeding or planning to be pregnant during the study
- •Having a dermatological condition liable to interfere with the study data or considered by the Investigator hazardous for the subject or incompatible with the study requirements
- •Having an ophthalmological condition liable to interfere with the study data or considered by the Investigator hazardous for the subject or incompatible with the study requirements
- •Having personal medical history liable to interfere with the study data for the subject or incompatible with the study requirements
- •Having history of abnormal reactions from exposure to sunlight
- •Having taken any previous treatment considered by the Investigator liable to interfere with the study data or incompatible with the study requirements
- •Being under any treatment considered by the Investigator liable to interfere with the study data or incompatible with the study requirements
- •Subject who is not likely to be compliant with study-related requirements
- •Subject deprived of freedom by administrative or legal decision or under guardianship
- •Criteria related to investigational product application areas:
- •Having had any surgery, chemical or significant invasive dermotreatment on the experimental area considered by the Investigator liable to interfere with the study data, before the inclusion visit or foreseeing it for the duration of the study
- •Having applied a skincare or make up product on the study areas the day of the inclusion visit. The usual cleanser is allowed
- •Having received, on the study areas, artificial UV exposure or excessive exposure to natural sunlight within the 2 weeks before the inclusion visit (at Investigator's opinion)
结局指标
主要结局
Global tolerance assessment of the investigational product by dermatological evaluation
时间窗: Change from baseline to just after application and to 3 weeks later
Dermatological evaluation based on physical and functional signs assessment by the dermatologist
Global tolerance assessment of the investigational product by ophthalmological evaluation
时间窗: Change from baseline to just after application and to 3 weeks later
Ophthalmological evaluation based on physical and functional signs assessment by the ophthalmologist
次要结局
- Cutaneous sensitivity by stinging test(Change from baseline to 3 weeks later)
- Cutaneous sensitivity by sensitivity scale questionnaire(Change from baseline to 1 week and to 3 weeks later)
- Soothing efficacy by a questionnaire(Change from just after application to 1 week and to 3 weeks later)
- Cosmetic acceptability and efficacy perceived questionnaire(After 3 weeks of tested product)